AstraZeneca, the British drug maker has developed a new anti-cancer drug, which is to be used for patients for whom all other treatment has failed.
Called Tagrisso, as also AZD9291, is one of the new molecules developed by the company to bolster sales, after it lost it’s patents on drugs developed years back.
Tagrisso is aimed at targeting mutated lung cancer cells which evade regular treatment. A symbiotic detection test developed Roche has also won a preliminary approval.
This drug, whose potential annual sales have been pegged at $ 3 Billion, would go a long way to bolster the top and bottom line of the company, while providing relief to the thousands of sufferers globally.